Full Year 2024 Results Key Financial Results Revenue: ...
Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.
J.P. Morgan analyst Casey Woodring maintained a Hold rating on Charles River Labs (CRL – Research Report) yesterday and set a price target of ...
As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced ...
Q4 2024 Earnings Call Transcript February 19, 2025 Charles River Laboratories International, Inc. beats earnings expectations ...
The FDA, NIH and CDC has cut 5,200 probationary staff in a job cull across the HHS over the Valentine's Day weekend.
Barclays lowered the firm’s price target on Charles River (CRL) to $160 from $166 and keeps an Equal Weight rating on the shares post the Q4 ...
Despite a challenging year, Charles River Laboratories International Inc (CRL) focuses on restructuring and strategic growth ...
A lower court properly threw out a securities suit alleging Charles River Laboratories International Inc. misrepresented its ...
Charles River's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. The company ended 2024 with about $195 million in cash, and it recorded a ...